UPDATE : Monday, February 17, 2020
상단여백
ViroMed confirms VM202’s pain control in animal test by Nam Doo-hyun 2018-04-18 11:39
‘Genexine’s pipelines worth more than ₩3 trillion’ by Nam Doo-hyun 2018-04-16 15:48
Obesity drug Saxenda’s sheds ‘1-year effect’ stigma by Nam Doo-hyun 2018-04-11 14:11
CG Bio wins nod for 3D printed artificial cheekbones by Nam Doo-hyun 2018-04-10 15:12
Boehringer Ingelheim Korea CEO was forced to resign? by Nam Doo-hyun 2018-04-06 16:10
라인
Pharmaceutical exports jumped 30% in first two months by Nam Doo-hyun 2018-04-05 15:09
Invossa’s encouraging trial results presented in US by Nam Doo-hyun 2018-03-28 15:05
Prescriptions of anticancer drugs surged in January by Nam Doo-hyun 2018-03-27 14:14
Opdivo adds gastric cancer to indications by Nam Doo-hyun 2018-03-27 11:34
Stem cell therapy developers unaffected by Cha Biotech debacle by Nam Doo-hyun 2018-03-26 15:58
라인
4 drugmakers’ profits turn to losses by Nam Doo-hyun 2018-03-21 11:38
Foreigners buy SillaJen, Samsung BioLogics, dump Celltrion by Nam Doo-hyun 2018-03-20 12:01
‘BMS’ Opdivo to lead cancer immunotherapy market’ by Nam Doo-hyun 2018-03-14 15:16
‘Demand for healthcare cloud service rising’ by Nam Doo-hyun 2018-03-12 15:03
‘Me Too’ movement spreads to pharma sector by Nam Doo-hyun 2018-03-08 11:48
라인
Will Invossa face rival cell gene therapy? by Nam Doo-hyun 2018-03-07 15:00
‘Order receipt to bolster Samsung BioLogics’ sales’ by Nam Doo-hyun 2018-03-06 15:58
Researchers find diagnostic biomarker for type 2 diabetes by Nam Doo-hyun 2018-03-05 12:16
Seoul spent ₩2 trillion for new drug development in 7 years by Nam Doo-hyun 2018-03-02 11:59
‘Korea needs genome data standardization' by Nam Doo-hyun 2018-02-28 11:31
여백
여백
여백
Back to Top